Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently amended) A conjugate having the general structural formula:

wherein L is a phospholipid <u>having a head group that is attached to the dithiobenzyl moiety</u>, R^1 represents a therapeutic drug covalently attached to the dithiobenzyl moiety, and where orientation of the CH_2R^1 group is selected from the ortho position and the para position.

2. (Original) The conjugate of claim 1, wherein the therapeutic drug is covalently attached by a linkage selected from the group consisting of urethane, amine, amide, carbonate, thio-carbonate, ether and ester.

3-6. Cancelled

- 7. (Original) The conjugate of claim 1, wherein said drug is selected from the group consisting of mitomycin C, mitomycin A, bleomycin, doxorubicin, daunorubicin, fluorodeoxyuridine, iododeoxyuridine, etoposide, AZT, acyclovir, vidarabine, arabinosyl cytosine, pentostatin, quinidine, atropine, chlorambucil, methotrexate, mitoxantrone and 5-fluorouracil.
- 8. (Original) The conjugate of claim 1, wherein the therapeutic drug is covalently linked to the dithiobenzyl moiety to form a conjugate having the structure:

wherein R⁴ represents a residue of the therapeutic drug.

- 9. (Original) The conjugate of claim 8, wherein R⁴ is a therapeutic drug residue containing a primary or a secondary amine moiety thereby forming a urethane linkage between the dithiobenzyl and the therapeutic drug.
- 10. (Original) The conjugate of claim 9, wherein said therapeutic drug is selected from the group consisting of mitomycin A, mitomycin C, bleomycin and a polypeptide.
- 11. (Original) The conjugate of claim 8, wherein R⁴ is a residue of a carboxylcontaining therapeutic drug, thereby to form an ester linkage between the dithiobenzyl and the therapeutic drug.
- 12. (Original) The conjugate of claim 11, wherein said drug is chlorambucil or methotrexate.

13-14. Cancelled

15. (Previously presented) A liposome composition, comprising liposomes comprised of vesicle-forming lipids including from about 1 to about 30 mole percent of a conjugate according to claim 1.

16-42. Cancelled